Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis

Abstract

Objective: To evaluate the efficacy of atorvastatin combined with febuxostat in the treatment of gout patients with carotid atherosclerosis and to observe the effects on serum tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and C-reactive protein (CRP) levels, carotid plaques, and the adverse reactions.
 Methods: Seventy patients with gout and carotid atherosclerosis admitted to Affiliated Hospital of Hebei University from January 2014 to June 2017 were randomly divided into a treatment group and a control group. The treatment group received oral febuxostat 40 mg/day combined with atorvastatin 40 mg/day. The control group was given 40 mg/day febuxostat combined with 20 mg/day atorvastatin for 90 days. The effects of treatment on TNF-α, IL-1β, and CRP levels and carotid plaques of the patients were observed.
 Results: After 90 days of treatment, serum TNF-α, IL-1β, and CRP levels, as well as HUA and total cholesterol (TC), decreased in both groups after treatment. There were significant differences observed (p < 0.05). The carotid artery plaques in the two groups were significantly smaller after treatment (P<0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05).
 Conclusion: Double doses of atorvastatin combined with febuxostat can effectively reduce uric acid to improve the inflammatory state in patients and reduce carotid plaques without increasing the incidence of adverse reactions.
 doi: https://doi.org/10.12669/pjms.36.6.2945
 How to cite this:Zhang Z, Xu MH, Wei FJ, Shang LN. Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci. 2020;36(6):---------. doi: https://doi.org/10.12669/pjms.36.6.2945
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Association Between Serum Uric Acid and Carotid Intima-Media Thickness in Different Fasting Blood Glucose Patterns: A Case-Control Study

“…This, in turn, forms a vicious cycle of hyperuricemia and subsequently triggers or aggravates cardiovascular disease ( 59 ). Moreover, several studies have confirmed that SUA-lowering therapy can improve outcomes of patients with a cardiovascular or cerebrovascular disease to a certain extent ( 60 ).…”

Additional Acupuncture Confers a Favorable Long-Term Prognosis for Elderly Hypertensive Patients with Carotid Atherosclerosis after Atorvastatin Treatment

“…Furthermore, when comparing the changes of BP and blood lipids, we found that the BP improvement of patients in the study group was more significant, which also shows that AP + ATO is more suitable for EH patients with CA. ATO, one of the most commonly used drugs for regulating blood glucose and blood lipids in clinical practice, can reduce cholesterol synthesis, increase LDL receptor synthesis, and reduce blood cholesterol and LDL-C levels [ 16 ]. The protein binding rate of ATO is about 98%, most of which are excreted in the bile in the form of metabolites, with relatively stable drug safety.…”

Efficiency of Febuxostat in Gout Patients with Arterial Hypertension and Reduced Glomerular Filtration Rate: An Exploratory Study

“…Additionally, during the treatment was reduced a level of total cholesterol, although not statistically signifi cant. There is evidence in the current literature of the eff ects of urate-lowering therapy on atherosclerosis, for instance, a study work of 2020 showed that a double dose of atorvastatin in combination with febuxostat can eff ectively reduce uric acid level, improve the "infl ammatory profi le" of patients and infl uence carotid plaques without increasing side eff ects [10]. It is known that uric acid crystals activate NLRP3 infl ammasomes, leading to the formation of high levels of IL-1β and IL-18, which is characteristically to acute attacks of gout, and cholesterol activates the same infl ammasome before occurrence of atherosclerotic lesions [5][6][7].…”

“…In addition, hyperuricemia correlates with number of infl ammatory parameters levels, such as white blood cell quantity, CRP, ESR, IL-6, IL-1, IL-18 and TNF [7,10,21], which are involved in the development of acute gout arthritis. In the current study, it was found a statistically signifi cant reduction of levels of infl ammatory parameters such as CRP and ESR.…”

“…The authors made a conclusion that combination of febuxostat with atorvastatin allows to reduce the serum uric acid level and the level of proinfl ammatory cytokines. Also it allows to reduce the grows of carotid plaques [10]. Patients with third and fourth stage of chronic kidney disease had a higher glomerular fi ltration rate (GFR) in the febuxostat group compared with the placebo group [11,12].…”